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O&j~ct&~. The purpose of this study was to determine whether 
the kinetics of smooth muscle cell outgrowth from in vitro explants 
0 n atber~clerotic ssue is de~nde~t on the ntttuw of the 
a lerotic lesion in viva, 
~~~~~~u~~, The use of techniques for in vivo 
extraction ofatherosclerotic plaque 
tudy human athe~oma~dcriv~~ s 
wever, because ofcell selection 
vitro endings may not always reflect the biologic properties ofthe 
, particularly if cells are in culture For prolonged 
contrast, studies with nonhuman cells have suggested 
that the rate at which cells grow out of tissue xplants i closely 
related to the status OF the cells in vivo. 
&fethods. Atherosclerotic ssue From 41 lesions, including 
primary plaques (From peripheral arteries and venous bypass 
conduits) and restenotic lesions (from peripheral rteries and 
venous conduits) were divided into a total of 1,5 
placed in culture on fibronectinecoated wells. E 
was scored over the ensuing 1month to determine the prevalence 
and time course OF smooth muscle cell outgrowth and the total 
cellular accumulation. 
&?esu&s. ~xpl~t hagments from 40 (98%) of tbe 41 lesions 
ieldcd an outgrowth of smooth muscle cells, confirmed by 
t~hemi~ry mean p~o~~tian of adher~~~t explant 
yielding out th, per lesion, was 69 zt 4% and was 
Migration and proliferation of vascular smooth muscle cells 
are central to the pathobiology of atherosclerosis (l-3). 
However, the rates at which these events take place are 
likely to be unique for a given lesion at a given stage of 
development. In advanced ath rosclerotic plaques, cell rep- 
lication rates may be very low (4) and cell migration i to the 
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higher in restenotic tissue 
lesions (p < 0.05). 
explant outgrowth From a varie 
types obtained intrao~rativeiy 
outgrowth From restenotic tissue IS 
lesion may be minimal at this stage. In contrast, in acceler- 
ated forms of atherosclerosis, such as restenosis after bal- 
loon angioplasty, migration of smooth muscle cells into the 
intima and cell proliferation probably take place at much 
higher ates (5). Thus, the stage and growth status of an 
atherosclerotic lesion appear to be determined in part by the 
activity or growth status of the smooth muscle cells within 
the lesion. 
A reliable and practical means of assessing the growth 
behavior of smooth muscle cells in human lesions would 
allow characterization of the proliferative status of a given 
lesion. Although present methods for such an assessment of 
human atherosclerosis are limited, the ability to retrieve 
portions of atherosclerotic plaques by directional therec- 
tomy has provided new opportunities for this type of evalu- 
ation. 
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nature of the lesion itself. If so, then monitoring the in vitro 
outgrowth of cells from atherosclerotic ssue fragments 
could provide a means of assessing irn~o~a~t biologic fea- 
tures of the lesion, such as growth status. Accordingly, we 
have used the explant outgrowth technique to initiate t 
growth of vascular smooth muscle cell 
lerotic lesions from 
percutaneously or in 
e tested the hypothesis that the kinetics of 
smooth muscle cell outgrowth from explanted tissue frag- 
ments is dependent on the nature of the lesion from which 
the cells originated. 
e. A total of 41 athero- 
sclerotic lesions were obtained in vivo from 39 patients by 
one of two means. In 35 patients, 37 lesions were retrieved 
percutaneously by therapeutic directional therectomy using 
the Simpson AtheroCath (Devices for Vascular Interven- 
tion) according to previously described techniques (13). The 
atherectomy site was determined by an angiogram per- 
formed immediately before the atherectomy. In four pa- 
tients, four lesions were obtained iotrao~erat~v~~y. 
The lesions were categorized aseither primary or resten- 
osis lesions. Twenty (48.8%) of the 41 lesions were primary 
atherosclerotic lesions, so designated because r vasculariza- 
tion of these lesions had not been previously attempted. Of
these 20 lesions, 14 were obtained percutaneously from the 
superficial femoral artery (n = iO), the iliac artery (n = 3) or 
the poplited (n = 1) artery. The remaining six primary 
Lesion Type 
Prkary Weslenotic 
Peripheral Vein Peripheral Vein 
Artery Graft Artery Graft 
Mean age of patient (yr) 64+3 70+4 - 6824 77 I+. I 
PIumber of lesions 14 6 I6 5 
Adherent explants/lesion 34 2 7 i0 ? f 52 I 10 45 + 14 
Explants/lesion with 52 + 7 692 13 78 ” 4* 92 5 4* 
SMC outgrowth (%) 
_ -_-_- 
*p < 0.05 versus primary peripheral arrery IesLn. SMC = smooth muscle 
cell. 
lesions were obtai 
patients ~~dergo~~g repeat c
and two patients u~der~oi~~ 
plaque in an ~leofemora~ byp 
can of 8.7 -+ t .1 years (range 5.9 to 
Twenty-one (40.7%) of tke 41 lesions were restenosis 
were retrieved percutaneously from t 
teal (n = 2) artery. Pei-cuta- 
in these 16 cases ifl~~~~e~ 
, combined laser and balloon 
a~gio~~asty (n = 5), 
combined laser angio 
etween the initial 
current atherectomy was 6.9 f 0.7 (range 1.8 to 12.3) 
months. The remaining five restenosis lesions were retrieved 
~rcutaueous~y from recurrent lesions 
covetous grafts. One of the five 
rgone balloon embolectomy and ectional atherec- 
tomy 5 and 2 weeks, respectively, before the current 
atherectomy procedure. The other four patients had under- 
gone percutaneous directional therectomy between I and 8 
months after balloon angioplasty atthe same site. 
There were no differences in the mean ge of the patients 
from whom the four types of lesions (peripheral rtery 
primary, peripheral rtery restenosis, vein graft primary and 
vein graft restenosis) were obtained (Table 1). The wet 
weight of the atherectomy samples ranged from 16 to 
c. In all cases, the retriev 
free culture med 
transposed tothe culture 
were then washed with fresh medium after w 
side was gently scraped with a scalpel blade to dislodge 
endothehal cells. For samples retrieved by directional 
atherectomy, this procedure was facilitated by the use of a 
dissecting microscope (Zeiss, Rainin Instrument). 
1432 PICKERING ET AL. 
HUMANSMOOTHMUSCLE CELLOUTGROWTH 
JAW Vol. 20. No. 6 
November IS. 1992: 1430-g 
Poor adherence of atherosclerotic tissue to the culture 
substrate has been a limitation of SuccPSSfUl iuhure Of 
plaque-&rived human smooth muscle cells (14). PrecoatiW 
the surface of plastic culture dishes with fibronectin has been 
shown to promote adhesion of vascular smooth muscle Cells 
to the substrate (15). In preliminary experiments we had 
therefore sought to determine if similar pretreatment would 
increase the adherence of the entire explant. Human Plasma 
fibronectin prepared from plasma Cohn fractions was gener- 
ously provided by R. Weinstein. A total of 174 fragments of 
explanted tissue were placed either in untreared culture 
wells, wells wetted with sterile phosphate-buffered saiine 
solution (GIBCO Laboratories) or wells precoated with 
tibronectin (IO pg/cm’). After 5 days, the proportion of 
adherent explants was significantly higher in fibronectin- 
coated wells (97 9 4%) than in saline-treated (76 -C 5%) or 
untreated culture wells (72 -t- 14010, p < 0.05). 
All specimens were therefore placed into Abronectin- 
coated &well plastic culture dishes and subsequently cut 
into I- to Z-mm fragments. id fragment was then im- 
mersed in a drop of culture medium supplemented with 15% 
fetal bovine serum (GIBCO Laboratories) and placed in a 
humidified incubator (5% carbon dioxidel95% air) at 37°C. 
The explants were allowed to attach to the surface of the 
culture well during the next I2 to 18 h, after which an 
ddibional 1 ml of serum-supplemented (15%) culture me- 
dium was added. Medium was exchanged every 2 days after 
the onset of cell outgrowth. 
Explants were initially left undisturbed to increase the 
likelihood of adherence, and first examined after 5 days in 
culture. Every 2 days thereaflctr the specimens were scored 
to determine the number of explants yielding an outgrowth 
of smooth muscle cells. Scoring wds continued for approxi- 
mately 3 weeks, by which time the proportion of explants 
with outgrowth was constaFt. Explants that had not adhered 
to the substrate were not included in the analysis. The time 
course of outgrowth (number of explants with an outgrowth 
of muscle cells vs. days in culture) was plotted for each 
lesion and the half-maximal outgrowth (time until 50% of the 
explant pieces that ultimately yielded an outgrowth had 
initiated outgrowth) was determined by linear interpolation. 
Twenty-one days after the half-maximal outgrowth was 
reached. the tissue fragments were rcmovl;.d and the cells 
were enzymatically dispersed (0.25% trypsin, I mM ethyl- 
enediaminetetraacetic acid [EDTA]), pooled, and counted 
with a hemocytometer. The in vitro accumulation of vascu- 
lar smooth muscle cells was expressed as the total number of 
cells per adherent explant, 
Smooth muscle cells from six peripheral artery lesions 
(three primary, three restenosis) were used to compare the 
deowhnucleic acid (DNA) synthesis rates between cells 
derived from primary lesions and celfs derived from resteno- 
sis !esions. In each case, the smooth muscle cell outgrcwths 
were trypsinized, seeded on to fibronectin-coated wells at a 
density of 5,000 cells/cm2 and incubated with serum (IO%)- 
supplerented M199. Seventy-two hours after seeding, they 
were incubated for 4 h with [‘HI-thymidine (6 &i/ml, 6.7 
Ci/mmol, New England Nuclear). Cells were then washed 
with phosphate-buffered saline solution, followed by 3 10. 
min washes in ice-cold 10% tricbloroacetic acid. Cells were 
solubilized ~a 0.25 N sodium hydroxide and radioactivity 
was determined by liquid scintillation counting. Duplicate 
wells of cells from each lesion were studied and cells from a 
primary and a restenosis lesion were assayed simulta- 
neously. 
~mrnuaocyto~~~~~st~y. Cells growing in both the out- 
growth phase and in first subcultures were studied by 
immunocytochemist~y. To study outgrowing cells, explants 
were placed directly on to multiwell slides. Cells were faxed 
in acetone and immunostained with the use of monoclonal 
antibodies directed against alpha-smooth muscle actin 
(Clone IA4, Sigma Chemical), Factor ~~~~-related antigen 
(Signet Laboratories) and macrophages ( 
agnostics). Primary antibody was visualized by incubating 
with fluorcqcein isothiocyanate-labeled secondary antibody 
and cu3mining with epifluorescence microscopy (Nikon. 
Diaphot). 
Statistics. Results are expressed as filean value -+ SE 
Comparisons between the outgrowth variables of primary 
and restenotic tissue were made by Student t test. Values 
were also subcategorized on the basis of lesion type and 
source and compared by ose-way analysis of variance, with 
the Scheffd post-hoc test. Statistical significance was set at 
p < 0.05. The proportion ofoutgrowing explants at each rime 
point was compared between peripheral artery primary and 
restenotic lesions by Y test. For this comparison, statistical 
significance was set at p < 0.01 to protect from an increased 
risk of type I error due to multiple comparisons. 
Lesion rno~~h~~Q~y: gross ~~a~acter~st~~s. The gross ap- 
pearance of primary lesions was variable. Lesions from the 
peripheral artery were generally yellow-white with multiple 
foci of a deeper yellow hue and occasional flecks of throm- 
bus on the lumen surface. Grossly apparent calcific deposits 
were frequently noted. Primary lesions retrieved from the 
saphenous vein grafts were similar in appearance to those of 
the peripheral artery e.a,cept that they were generally not 
calcified. 
The appearance of the restenotic lesions (peripheral ar- 
tery and vein) was more hnmog,,~eneous, typical!;1 white to 
white-gray with no overt evidence rrf calcifi 
of smooth muscle cells was observed from explants from 40 
(98%) of the 41 lesions. Generally, after a lag of a few days, 
spindle-shaped cells appeared at the margins of the explant. 
These cells subsequently proliferated covering varying 1:’ o- 
portions of the floor of the culture well. There was no 
outgrowth from explants that had not adhered to the bottom 
of the dish. Cells were identified as smooth muscle cells by 
their tendency to form multilayered growth patterns (16), 
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and by positive staini g on im~~nocytochemistry 
monoclonal smooth scle alpha-actin antibody. 
revealed longitudinally arranged filaments indicative of 
actin-based stress fibers (Fig. 1). Fift percent to 30% of 
cells in the outgrowth phase and 
positively stained; the fact that all c 
positive staining with the 
with other eports (8,14) a 
expression ofmuscle-sp 
muscle cells of plaque o 
growing in culture, or both (17). No stress ~ber-staining was 
observed when the primary antib was omitted from the 
immunostaining procedure. In so explants, spheric ells 
migrated out of the tissue with the smooth muscle cells, at
times before outgrowth of the smooth muscle cells occurred. 
These cells were identified as macrophages by positive 
immunostaining of the cellular outgrowth with the HA 
antibody (18). There was no further accumulation f these 
cells after approximately 11 days, and they were not present 
in subcultures. lmmunostaining forFactor VIII-related an- 
was negative inboth outgro 
evalence of smooth muscle 
picts the prevalence of smooth muscle cell outgrowth for 
each type of lesion. The mean umber of explant fragments 
per specimen was 39 + 5. b-r only one instanre did none of 
the explant fragments from a specimen result in an out- 
growth of smooth muscle cells. The single instance in which 
this occurred involved a heavily calcified primary peripheral 
artery ptaque from a 6R-year old man. Including this speci- 
men, the proportion of adherent explant fragment yielding 
outgrowth among the 41 lesions was 69 f 4%. This propor- 
tion varied according to the nature of the lesion. Specihcally, 
the prevalence of outgrowth from the restenotic lesions 
utgrowtb proceeded most 
from restenotic lesions (a 
Ftgure 2. Half-maximal outgrowth values for the four wbcategories 
of plaque. This variable is an indicator of the time required fora 
given lesion to initiate migration of smooth muscle cells in vitro. 
*p < 0.05 versus primary peripheral rtery (PA) or primary vein 
graft (VG). 
Primary PA A Primary WQ Restrnotic V13 
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Figure 3. Time course of initiation of smooth muscle cell outgrowth 
from explants of primary atherosclerotic and reslenotic lesions of 
peripheral arteries. The initiation of outgrowth was considerably 
more prompt in the rcstenosis lesions. Closed squares = primary 
lesions; open circles = restenotic lesions. ‘p < 0.01 I 
values for the peripheral artery lesions (primary and rest- 
enotic) yielding outgrowth are depicted in Figure 3. The 
initiation of outgrowth was clearly more immediate in the 
restenotic lesions. By 5 days, smooth muscle cell outgrowth 
had begun among 32 2 4% of the explants from restenotic 
lesions versus 9 +- 5% of explants from primary lesions (p C 
0.001). Statistically significant differences between the 
groups persisted throughout the outgrowth period. 
Rate of cell accumulation around explant fragments, The 
rate of accumulation f cells around the explant was lso 
substantially higher in tissue from restenotic lesions than 
from primary plaque. Twenty-one days after the half- 
maximal outgrowth was attained, the total number of cells 
per adherent explant was 2,791 .Z+I 631 for restenotic tissue 
and 653 zz I44 for primary tissue (p < 0.01). This difference 
persisted if the single primary’peripheral artery lesion with 
no outgrowth was excluded from the analysis. Data for the 
lesions ubcategorized by type and source are shown in 
Figure 4. The S-day outgrowth ofsmooth muscle cells from 
both a primary and a restenotic lesion, together with the 
corresponding histologic findings, is illustrated in Figure 5. 
The 15.day outgrowth of cells from a primary and a reste- 
notic lesion, together with the corresponding angiographic 
findings, is illustrated inFigures 6 and 7. In each instance, 
outgrowth was present from both the primary and the 
restenotic lesions; however, itwas considerably more abun- 
dant from the restenotic tissue. 
Within the four subgroups the e were no correlations 
between the age of the patient anA either the half-maximal 
outgrowth or the cell accumulation rate. 
Thymes inmrporation. Thymidine incorporation was 
determined 3 ays after seeding first-passage smooth muscle 
cells. Uptake of 13Hl-thymidine was significantly higher in 
cells from restenotic lesions than in ceils from primary 
lesions (7,166 2 277 vs. 5,651 5 307 counts/min, p < 0.05). 
Extent of smooth muscle cell outgrowth for the four 
subcategories of plaque. Cells were counted %I days after the 
half-maximal outgrowth was attained. *p < 0.05 versus primary 
peripheral artery iPA) or primary vein graft 0KI. 
This study represents he Srst attempt to quantify out- 
growth of smooth muscle cells from human atherosclerotic 
plaque placed in culture and to determine whether the 
kinetics of this outgrowth reflects the nature of the lesion. 
We have specifically compared the outgrowth responses of
primary and restenotic lesions. 
Cell culture, in general, provides a valuable system for 
studies on the re~Mlatio~ and control of smooth muscle cell 
behavior. By simplifying and controlling the environment, 
one is able to assess avariety of cellular events relevant to 
vascular biology. A traditional method of evaluating growth 
properties i  to generate growth curves by serially counting 
subcultured cells at various intervals after seeding. This 
characterizes clearly the proliferative profile of the cells. 
However, the cell-counting approach typically necessitates 
multiple subcultivation to obtain sufficient cells for the 
analysis. It is well recognized that he growth characteristics 
of cells in primary culture will change with time because of 
the selection of cell clones with the greatest capacity to 
proliferate (19). Furthermore, the low initial cell yield from 
atherectomy aterial may preclude this as a routine form of 
analysis. Dartsch and coworkers (9), for example, found that 
growth curves could not be generated for cells derived from 
I4 of I9 primary lesions studied because of insufficient cell 
yield. 
We have examined the behavior of smooth muscle cells 
as they grow directly out of intact explants of at~~~osc~er~t~c 
tissue. From a practical standpoint, our experience and that 
of others (9.20) has shown that initiating cell growth from 
atherectomy tissue by explant tgrowth is more successful 
than is initiating it by enzymati spersion of cells within t
plaque. Furthermore, both cell migration and proliferation 
underlie the phenomenon f cellular outgrowth from vascu- 
lar explants (21) and although quantifying outgrowth kinetics 
stem the relative role of each, it p 
ard means of assessing the ~o~~i~ed 
these important cellular events s Ly after the tissue has 
been placed in the ex vivo environment. The kinetics of 
outgrowth may also reflect he rate at which cells in the 
explant adapt or respond to the growth- 
environment. This in turn is a fm-kctioa f the status of the 
Figure 5. Five-d&v cell outgrowth from a peripheral rtery primary 
artery restenotic lesion 
micrograph of a section 
e right (elastin trichrome 
m the primary lesion is 
early stage. The corresponding histologic features demonstrate the 
paucity of cells within this lesion. In contrast, a dense population f 
cells has already accumulated round the restenotic tissue. The 
lesion itself was highly cellular. E = explant. 
Fi 6. Angiographic findings and cor- 
re ding ‘O-day smooth muscle cell 
outgrowth from a primary lesion re- 
trieved by directional thenctomy from 
the superficial femoral artery. a, Angio- 
gram taken before atherectomy; the 
arrow depicts the site of total occlusion. 
Angiogram taken after atherectomy. 
e: Fifteen-day outgrowth ofcells from a 
fragment of the retrieved tissue. There is 
ttered th of smooth muscle 
E= 
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Figure 7. Angiographic findings and corresponding U-day smooth muscle cell outgrowth 
from a restenotic lesion retrieved by directional atherectomy from the superficial femoral 
artery. a, Angiogram taken before balloon angioplasty; the arrow denotes the site of total 
occlusion. b, Angiogram taken after balloon angioplasty. c, Angiogram taken 5 months 
after balloon angioplasty showing restenosis at the site of the previous intervention; the 
arrow denotes the site of maximal restenosis. d, Fifteen-day outgrowth of smooth muscle 
cells from a fragment of the retrieved restrnotic tissue, showmg a dense population of cells 
surrounding the explant (El. Bar = 500 pm. 
original tissue. Grunwald and Haudenschild (IO), for exam- 
ple, observed that smooth muscle cell outgrowth from ex- 
plants of balloon--injured at aorta occurred more frequently 
and earlier than did outgrowth from explants prepared from 
sham-operated controls. 
e have found that use of the explant outgrowth tech- 
nique provides a highly successful means of cultivating 
smooth muscle cells from a variety of human plaque types 
and that the outgrowth kinetics of these cells is indeed 
dependent on the type of the lesion. 
Success of smooth muscle cell outgrow8 
atheroma. Use of the explant outgrowth tecnnique requires 
resolution of the tendency for atherosclerotic issue to float 
off of the floor of the culture dish (14). An approach that has 
been used previously (7,8,14) involves embedding the ex- 
plants in a collagen gel. We found that by simply precoating 
the surface of the culture wells with 
almost all of the explant fragments adhered to the surface. 
The use of fibrtiqectin may also offer the advantage of
promoting cell gnrwth (22). In this regard we did not find it 
JAW Vol. 20, No. 6 
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substrate. 
explants of restenotic tissue is consistent wit 
nence of smooth muscle cells in these lesions. 
histologic analyses of restenotic lesions obtained by atherec- 
tomy from peripheral rteries (11) coronary arteries (25-27) 
and saphenous vein grafts (27) have consistently demon- 
strated an abundance of ioose byper~ias~~c tissueprimarily 
comprising smooth muscle ells. In cor;irast, primary lesions 
are characterized by a lower content of s~~ootb muscle cells 
and a higher volume fraction of dense collagen, necrotrc 
de lipid a 
etics of 
atheroma. Role of smooth mud 
set of outgrowth from restenotic lesions proved to occur 
significantly sooner thau that of primary lesions regardless of 
the source of the lesions. Primary and restenotic lesions 
were also distiuguishable in vitro by the rate at which the 
outgrowing cells accumulated around the explant. This rate 
I was approximate.;‘. “our times as high for the cells originating 
from restenotic lesions than for those originating from pri- 
mary lesions. These differences may be partly accounted for 
by differences in the nitial number of 
explanls of primary an restenotic plaque. 
subcult:rred aud seeded at identical de 
itdine ~nco~orat~on was significantly 
rigmating from restenotic atheroscl 
finding is consistent with the observation by Dartsch and 
coworkers (9) that cells derived from restenotic tissue have 
shorter doubling times than those from primary lesions. 
muscle cells that are in e 
h irk vitro. conversely, 
ore slowly than do cells from 
senescence, having ~ndergo~ erous doodlings over the 
course of lesion formation i  than those of restenotic 
lesions. Ross et al. (6) observed that the degree of growth 
to increasing concentrations 
h muscle cells derived from p 
than in ceils from the und 
this pattern was consistent with the 
existence ofa relatively senescent population of cells within 
primary plaque. In the present study, therefore, the rela- 
tively slow outgrowth kinetics from primary lesions 
due in part to cellular senescence. In turn, the mo 
00th musclle cells fr restenotic ttssue 
cry recent migration 
and the relatively fe 
itrjuem*es on o~~g~ow~h kinetics. ther factors 
mooth muscle cell e may have 
influenced outgrowth kinetics. The amount and biophysicai 
properties ofthe extracelhmlar matrix components probably 
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influence smooth muscle cell migration and proliferation 
in vivo and may similarly influence the c llular outgrowth 
in vitro. Our current results uggest that the extracelhdar 
milieu of restenotic tissue may be more favorable tocellular 
migration and proliferation than is that of primary tissue, 
although this possibility remains speculative. Mer 
extracellular f ctors that could modulate outgrowth kinetics 
include growth and migration factors. Several secreted 
peptides, including platelet-derived growth factor (33,341 
and basic fibroblast growth factor (3% have been assoc- 
iated with accelerated vascular disease in animal models 
and an increased concentration f these factors in human 
restenotic tissue could conceivably facilitate outgrowth in 
vitro. 
Some technical factors could potentially have affected 
explant outgrowth. As indicated, pretreatment of he culture 
wells with fibronectin greatly facilitated successful culture of 
the cells of interest. Howev~, fibronectin itself may pro- 
mote the transformation f vascular smooth muscle cells in 
vitro, and possibly in vivo. from the contractile to the 
synthetic phenotype (22). This alteration could conceivably 
affect outgrowth kinetics. Nevertheless, a clear distinction 
between the outgrowth responses of primary and restenotic 
lesions was still evident. Because fibronectin is already 
present in serum, further supplementation by precoating the 
culture dish may be insufficient to influence the outgrowth 
characteristics in a meaningful way. Another potential 
variable is the total area of explant tissue that is in cont:;ct 
with the culture substrate. However, any variation here is 
likely to have been randomly distributed among the 1,596 
explant fragments studied and is therefore unlikely to ac- 
count for the observed ifferences between primary and 
restetistic tissue. 
Conclusions, Clinically relevant biologic features of pri- 
mary and restenotic atherosclerotic plaque may be distin- 
guished by using an in vitro assessment of smooth muscle 
cell ou$rowth. By assessing the outgrowth kinetics of 
plaque-derived smooth muscle cells it appears possible to 
characterize the growth behavior of a given lesion and 
pel,haps topredict its response to mechanical interventions. 
Furthermore, this in vitro assay may prove to be valuable ror 
assessing the effect of agents designed to reduce intimal 
proliferation. 
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